French drugmaker Sanofi on Monday flagged another delay to a U.S. regulatory decision for its experimental multiple sclerosis ...
South Korea-based ADEL said late on Monday that it has entered a $1.04 billion partnership with French drugmaker Sanofi to ...
A U.S. regulatory decision on tolebrutinib will again be delayed while a late-stage trial of the drug for a different form of ...
French pharmaceutical group Sanofi said on Monday the U.S. Food and Drug Administration's decision on its investigative drug ...
Shares of Sanofi slumped on Monday as the French drugmaker said a U.S. regulatory review of its multiple-sclerosis drug won’t ...
We recently compiled a list of 9 Most Undervalued Pharma Stocks to Buy Right Now. Sanofi is among the most undervalued stocks ...
Sanofi sees continued growth and strong financials despite a pipeline setback. Click for this updated look at SNY stock ...
Sanofi’s efdoralprin alfa earns orphan designation in the EU for alpha-1 antitrypsin deficiency related emphysemaAdditional orphan designation ...
Pharmaceutical Technology on MSN
Sanofi signs pair of billion-dollar biotech deals to bolster pipeline
Sanofi has agreed $1.7bn and $1.04bn licensing deals with Dren Bio and ADEL, respectively. Following the disappointment of a ...
ADEL-Y01, a monoclonal antibody targeting tau protein, is in Phase I trials for Alzheimer's disease, developed by ADEL and ...
Sanofi’s multiple sclerosis hopeful tolebrutinib faced dual setbacks on Monday, with a late-stage failure in one form of the ...
Sanofi is back with its second pact of the day, this time announcing a licensing deal for a South Korean biotech’s antibody ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback